Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076837 | 0.87 | ALDH1A1 (0.59) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL4069047 | 0.83 | ALDH1A1 (0.68) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL28226906 | 0.82 | ALDH1A1 (0.77) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL31506498 | 0.81 | CA12 (0.45) | ALDH1A1NOTUMTSHRCYP3A4TDP1 | |
| SCHEMBL4064779 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL12706910 | 0.79 | ALDH1A1 (0.72) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL11874981 | 0.78 | ALDH1A1 (0.68) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL6257153 | 0.77 | ALDH1A1 (0.70) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| Hydrochloric Acid SCHEMBL10515108 | 0.76 | MAPT (0.71) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D | |
| SCHEMBL220303 | 0.75 | ALDH1A1 (0.66) | ALDH1A1SIGMAR1HTR3EHTR3BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0950048-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998025903-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
| EP-0837848-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997001536-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1997-01-16 | — | — | WO | disclosed |
| US-4691019-A | Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine | SANOFI (FR) | 1987-09-01 | — | — | US | disclosed |
| US-4602024-A | Substituted trifluoromethylphenyltetrahydropyridines having a cyano substituent and an anorectic activity, a process for preparing same and pharmaceutical compositions | SANOFI (FR) | 1986-07-22 | — | — | US | disclosed |
| EP-0060176-B1 | SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES HAVING ANORECTIC ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1985-01-02 | — | — | EP | disclosed |
| US-4472408-A | Substituted trifluoromethylphenyltetrahydropyridines having an anorectic activity | SANOFI (FR) | 1984-09-18 | — | — | US | disclosed |
| EP-0060179-A1 | Pharmaceutical compositions having anorectic activity | SANOFI S.A. (FR) | 1982-09-15 | — | — | EP | disclosed |
| EP-0060176-A1 | Substituted trifluoromethylphenyltetrahydropyridines having anorectic activity, their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | ALDH1A1 334/4885SIGMAR1 1023/4885HTR3E 3220/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | ALDH1A1 334/4885SIGMAR1 1023/4885HTR3E 3220/4885 |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | ALDH1A1 1697/4885SIGMAR1 650/4885HTR3E 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.